Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.82 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.75 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924204 | 0.94 | NTRK1 (0.83) | NTRK1NTRK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1924757 | 0.90 | NTRK1 (1.00) | NTRK1NTRK2MEN1KMT2APDGFRB | |
| SCHEMBL1925139 | 0.88 | NTRK1 (0.79) | NTRK1NTRK2ERN1PDGFRBRIPK1 | |
| SCHEMBL1924695 | 0.88 | NTRK1 (0.85) | NTRK1NTRK2MAPTHTTRAB9A | |
| SCHEMBL1925796 | 0.88 | NTRK1 (0.84) | NTRK1NTRK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1925269 | 0.88 | NTRK1 (0.88) | NTRK1NTRK2PDGFRBKDRAURKA | |
| SCHEMBL1924937 | 0.88 | NTRK1 (0.88) | NTRK1NTRK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1924388 | 0.87 | NTRK1 (0.83) | NTRK1NTRK2KMT2APDGFRBKDR | |
| SCHEMBL1925944 | 0.87 | NTRK1 (0.83) | NTRK1NTRK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1924680 | 0.87 | NTRK1 (0.83) | NTRK1NTRK2PDGFRBKDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885KCNJ6 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.